ANGLE looks to change the game for cancer detection after FDA approval for Parsortix

 

UK medical device company ANGLE has received FDA clearance for its Parsortix PC1 system, a first-of-its-kind device that can harvest intact cancer cells from a patient's blood sample for subsequent analysis. This is a significant milestone for the company, and it has the potential to revolutionize the way cancer is detected and managed.

The Parsortix system is a liquid biopsy device, which means that it can detect cancer cells in the bloodstream without the need for an invasive tissue biopsy. This is a major advantage, as it is less risky and more convenient for patients. Additionally, liquid biopsies can be used to monitor cancer progression and treatment response over time, something that is not possible with tissue biopsies.

The Parsortix system works by using a microfluidic chamber to capture cancer cells from the blood sample. The cells are then harvested and can be used for a variety of downstream assays, such as genetic testing or immunophenotyping. This information can be used to diagnose cancer, identify the type of cancer, and determine the best course of treatment.

The FDA clearance of the Parsortix system is a major validation of ANGLE's technology. It is also a sign of the growing interest in liquid biopsy testing as a way to improve cancer detection and management.

ANGLE is now looking to commercialize the Parsortix system in the United States. The company has already partnered with several leading cancer centers to begin using the device in clinical trials. ANGLE is also working to develop new assays that can be used with the Parsortix system to detect and monitor a wider range of cancers.

How the Parsortix system could change the game for cancer detection

The Parsortix system has the potential to revolutionize cancer detection and management in a number of ways:

·         Earlier detection: The Parsortix system can detect cancer cells at earlier stages than traditional tissue biopsies. This is because cancer cells often shed into the bloodstream before they can be detected by other methods. Earlier detection of cancer can lead to better outcomes for patients, as it allows for earlier treatment intervention.

·         More convenient and less risky for patients: Liquid biopsies are less invasive and risky than tissue biopsies. This is because they do not require surgery or other procedures to collect the sample. This makes them a more viable option for patients who are not able to have tissue biopsies, such as those who are elderly or have other health conditions.

·         Ability to monitor cancer progression and treatment response: Liquid biopsies can be used to monitor cancer progression and treatment response over time. This is not possible with tissue biopsies, as they can only provide a snapshot of the cancer at the time of the biopsy. The ability to monitor cancer progression and treatment response can help doctors to make better decisions about treatment.

Overall, the Parsortix system has the potential to revolutionize cancer detection and management by making it possible to detect cancer earlier and more conveniently, and to monitor cancer progression and treatment response over time. This could lead to better outcomes for patients and improved cancer survival rates.